TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04764955

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Description: The intervention is an oral tablet containing vitamin D3 (cholecalciferol). Each weekly dose consists of a single tablet. Vitamin D3 content of the dose depends on the intervention group.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Description: The intervention is an oral tablet containing vitamin D3 (cholecalciferol). Each weekly dose consists of a single tablet. Vitamin D3 content of the dose depends on the intervention group.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Description: The intervention is an oral tablet containing vitamin D3 (cholecalciferol). Each weekly dose consists of a single tablet. Vitamin D3 content of the dose depends on the intervention group.
Study: NCT02405663

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manual removal
Description: one of the standard procedures for placental delivery during caesarean section the surgeon will introduce his hand into the uterine cavity to cleave the placenta from the decidua basalis as soon as possible after the delivery of the baby

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cord traction
Description: one of the standard procedures for placental delivery during caesarean section the surgeon do external uterine massage and gentle traction on the exposed umbilical cord to facilitate placental delivery
Study: NCT03122340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropren
Description: Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
Study: NCT02189889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPO
Description: The treatment group will receive up to three doses of EPO 300U/kg. The first dose of study medication will be administered up to 28 days before the day of surgery and the second will be administered 1-7 days before the day of surgery. These first two doses will be given at least 7 days apart. A third dose may be administered two days following surgery. All 3 doses will be administered per surveillance strategy guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Feraheme
Description: Supplementation with Feraheme, 510mg delivered as an IV infusion, will be given following the first two preoperative doses of EPO.
Study: NCT03122340

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oil
Description: Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
Study: NCT01427842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEVINE vancomycin regimen
Description: The dosing regimen varies by weight and height and by initial or ongoing dose prescribed. The loading dose is based on actual volume of distribution of vancomycin whilst the ongoing doses are based on creatinine clearance.
Study: NCT04061642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clinical Decision Aid
Description: The Clinical Decision Aid is a predictive model that takes as input individual patient characteristics, called 'features', which are inputted by the physician or by patient self-report, and outputs a list of all possible treatments, with each treatment associated with a predicted efficacy (likelihood to achieve response and likelihood to achieve remission, each expressed as a percentage). The treatments, which may include any approved treatment for depression, will be ordered by efficacy and presented to the physician. Lifestyle interventions, such as exercise or mindfulness, which have an evidence base, but do not require formal regulatory approval, will also be outputted. The system will additionally produce a side effect profile for each pharmacological treatment recommended, including known side effects, modified by a prediction about which side effects may be more likely for a given individual based on their individual characteristics.
Study: NCT01045993

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heat Device
Description: 8-Hour Heatwrap

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Inactive wrap worn for 8 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: marketed analgesic
Description: 2 x 200 mg ibuprofen tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x placebo tablets
Study: NCT03898830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eon™ FR 1064 nm device
Description: The subject treatment area - abdomen, was treated with the 1064 nm wavelength laser.
Study: NCT02381626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEPA air purifier
Description: air purifiers to remove PM and volatile organic compounds will be placed in drivers cars

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEPA air purifier
Description: air purifiers to remove PM and volatile organic compounds will be placed in drivers cars

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Log-book
Description: PM and biological measurements
Study: NCT02030613

Intervention type: GENETIC
Group type: OTHER
Intervention: Blood test
Study: NCT00954317

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epidural placed low
Description: epidural placed low

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high epidural
Description: high epidural
Study: NCT00922350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HELIOX
Description: The nebulization was conducted in the same way that heliox + posture group, except the attitude of trunk, where the patients in this group did the Nebulizer with the trunk upright.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OXYGEN
Description: The NEBULIZATION was performed the same way as the heliox group, except for torso posture, where the patients in this group with the trunk upright Nebulizer Oxygen for cars have A NEBULIZATION.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HELIOX+POSTURE
Description: Patients underwent two carried by heliox nebulization associated with fenoterol (2.5 mg) and ipratropium bromide (0.25 mg). We used three ml of saline solution at 0.9%. For nebulization with heliox or oxygen, was used a system of distribution not invasive, semi-closed in a mask that is non toxic connected to a piece Y with a nebulizer in a follow and a bag of tank with a capacity for 2.5 L in the other connected with a valve action. This system was used so that there was a dilution gas. The proportion of 80:20 heliox was used (80% helium: 20% oxygen). To postural change in groups and heliox Oxygen + posture + posture, oriented to the participants to maintain an angle of inclination of the trunk and elbows supported on the thighs, measured from the anterior axillary line and lateral epicondyle of the femur, between 50th and 60th .
Study: NCT00922350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OXYGEN + POSTURE
Description: The NEBULIZATION was conducted in the same way that heliox + posture GROUP, however the patients in this group have the Oxygen for Carr A NEBULIZATION
Study: NCT04722484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189)
Description: Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189)
Description: Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189)
Description: Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189)
Description: Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189)
Description: Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)
Study: NCT01107405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol etabonate base (QD)
Description: Loteprednol Etabonate ophthalmic base once daily dosing for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol etabonate base (BID)
Description: Loteprednol etabonate ophthalmic base BID dosing for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol etabonate base (QID)
Description: Loteprednol Etabonate ophthalmic base four times/day dosing for 2 week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol etabonate suspension
Description: Loteprednol etabonate ophthalmic suspension dosed four times daily for 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of loteprednol etabonate
Description: Vehicle of loteprednol etabonate ophthalmic dosed once, twice or four times daily for 2 weeks.
Study: NCT00589979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidoderm (Lidocaine 5% Patch)
Description: Topical Patch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Topical Patch
Study: NCT02957149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Platelet-Rich Plasma
Description: Platelets that are collected from the subject during the radical prostatectomy, for prostate cancer. The platelets are concentrated in a device to 1,000,000 platelets/mL and applied topically once to the neurovascular bundle during the surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angel Concentrated Platelet Rich Plasma System
Study: NCT04528589

Intervention type: OTHER
Intervention: prenatal psychotherapy
Description: Prenatal psychotherapy to break intergenerational risk of adverse childhood events
Study: NCT02639390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Therapy
Description: Subjects will be placed in the robot and practice common upper extremity tasks involving grasping, manipulating and moving objects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: An occupational therapist will provide one-on-one individualized programs focused on arm function. Treatment will focus on practice of specific tasks, such as reach, grasp, transport and release of various objects between different targets. Progression is done by varying the shape, size and weight of objects, altering the end range of the target or increasing the speed of movement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Therapy
Description: An occupational therapist will provide one-on-one individualized programs focused on arm function. Treatment will focus on practice of specific tasks, such as reach, grasp, transport and release of various objects between different targets. Progression is done by varying the shape, size and weight of objects, altering the end range of the target or increasing the speed of movement.
Study: NCT04095065

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: itMatters
Description: Increase knowledge related to STIs, STI risk, alcohol impairment, condom use, alcohol use behavior tracking skill, testing \& treatment knowledge. Correct misperceptions regarding approval (injunctive norms) and prevalence (descriptive norms) of alcohol misuse \& sexual risk taking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: itMatters and itMatters Sexual Violence Prevention
Description: Increase knowledge related to STIs, STI risk, alcohol impairment, condom use, alcohol use behavior tracking skill, testing \& treatment knowledge. Correct misperceptions regarding approval (injunctive norms) and prevalence (descriptive norms) of alcohol misuse \& sexual risk taking. Additionally, increased knowledge related to sexual violence (prevalence, key definitions, individual rights and responsibilities, laws) and increased knowledge, efficacy, and intentions to use bystander behaviors during moments of sexual violence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: itMatters Well-being and itMatters Sexual Violence Prevention
Description: Increase knowledge related to sleep, including biological effects of sleep and sleep hygiene. Increase knowledge related to time management, including important definitions, sleep management strategies, and effective time management routines. Additionally, increased knowledge related to sexual violence (prevalence, key definitions, individual rights and responsibilities, laws) and increase knowledge, efficacy, and intentions to use bystander behaviors during moments of sexual violence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: itMatters Well-being
Description: Increase knowledge related to sleep, including biological effects of sleep and sleep hygiene. Increase knowledge related to time management, including important definitions, sleep management strategies, and effective time management routines.
Study: NCT01469039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 9072
Description: Intramuscular (IM) injection, 441 mg or 882 mg given monthly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for IM injection, given monthly
Study: NCT00698828

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Twice daily subcutaneous injections of placebo for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN11031 20 μg/kg
Description: Twice daily subcutaneous injections of SUN11031 20 μg/kg for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN11031 40 μg/kg
Description: Twice daily subcutaneous injections of SUN11031 40 μg/kg for 12 weeks.
Study: NCT02833883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-115
Study: NCT00705705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Network leader training
Description: Network leaders will receive a nine-session training segment designed to enable them to motivate their peer networks to reduce sexual risk. The sessions will teach the identified leader of each network how to communicate HIV prevention messages to other members of his or her personal social network. Leaders will be asked to share these messages with other members of their groups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard HIV risk-reduction counseling
Description: Participants will undergo interviews about their friendship groups, sexual behavior, substance abuse, STD treatment history, condom use, and beliefs about HIV/AIDS. Participants will undergo a brief session about HIV/AIDS prevention methods after the first interview.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard HIV risk-reduction counseling
Description: Participants will undergo interviews about their friendship groups, sexual behavior, substance abuse, STD treatment history, condom use, and beliefs about HIV/AIDS. Participants will undergo a brief session about HIV/AIDS prevention methods after the first interview.
Study: NCT00693121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amantadine hydrochloride
Description: 100mg administered orally twice daily x 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: capsule, identical to amantadine hydrochloride capsule, administered twice daily x 14 days
Study: NCT03050814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: 10 mg/kg intravenous (IV) over 30-60 min on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad-CEA vaccine
Description: Subcutaneous injection in the thigh prior to Avelumab on Day 1 of cycles 1, 2 3, 5, 7, 9; every 6 cycles thereafter.
Study: NCT03870256

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: Patient receive 600mic gm sublingual misoprostol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Patient receive 100 mic gm carbetocin IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TA
Description: The patient receives 1gm oral tranexamic acid
Study: NCT03050814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5mg/kg intravenous (IV) over 30-90 min on day 1 (Arm A) or 2 (Arm B). Part of the standard of care therapy.
Study: NCT03346525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intramuscular benzathine penicillin G (BPG) prophylaxis
Description: Intramuscular BPG prophylaxis (600,000 IU for children \<30kg, 1.2 million IU for children ≥30kg), every 28 days.
Study: NCT02731287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol
Description: The patient will be treated with 2 drops twice a day over the lesion and rub with the finger (no occlusive) for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patient will be treated with 2 drops twice a day over the lesion and rub with the finger (no occlusive) for 24 weeks
Study: NCT02546882

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: stromal vascular fraction
Description: 1million stromal vascular fraction was resuspended in 1 ml saline and transplanted for 1 cm2 area.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 1 ml saline was injected for 1 cm2 area.
Study: NCT05592821

Intervention type: PROCEDURE
Intervention: dental implant placement
Description: In both groups, dental implants of the same brand will be placed into the bone with the same protocol.

Intervention type: PROCEDURE
Intervention: dental implant placement
Description: In both groups, dental implants of the same brand will be placed into the bone with the same protocol.
Study: NCT00414570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18]F-FLT PET scan
Description: Injection of \[18\]F-FLT radiopharmaceutical followed by PET imaging.
Study: NCT03824951

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19 iCAR NK Cells
Description: Anti-CD19 iCAR NK Cells injection
Study: NCT01977365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Growth promotion based on child centered approach
Description: - Preventive consultations will be reorganized. From the child birth, a follow-up schedule will be establish in agreement with the mother, and the subsequent appointment will be renew at each meeting.~Ten contacts will be organized for children under two years. During the first year, the number of contacts will be limited to 6 at birth , 2 , 3, 4 and 9 months to complete the vaccination schedule and an additional contact at 7 months to allow monitoring during the introduction of complementary foods.~Four contacts will be held for the second year to 12, 15, 18 and 24 months to monitor the transition from complementary food to the family diet.~- Inclusion of Child Centered growth promotion approach. During preventive consultations, specific messages according to the child age, health and nutritional status will be developed, based on scientific evidences and adapted to the experience and knowledge of health workers.
Study: NCT00383071

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H5N1 vaccine
Description: Monovalent subvirion H5N1 vaccine (rgA/Vietnam/1203/2004) 90 mcg/mL Manufactured by Sanofi Pasteur Inc, Swiftwater, PA.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H5N1 vaccine
Description: Monovalent subvirion H5N1 vaccine (rgA/Vietnam/1203/2004) 90 mcg/mL Manufactured by Sanofi Pasteur Inc, Swiftwater, PA.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H5N1 vaccine
Description: Monovalent subvirion H5N1 vaccine (rgA/Vietnam/1203/2004) 90 mcg/mL Manufactured by Sanofi Pasteur Inc, Swiftwater, PA.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H5N1 vaccine
Description: Monovalent subvirion H5N1 vaccine (rgA/Vietnam/1203/2004) 90 mcg/mL Manufactured by Sanofi Pasteur Inc, Swiftwater, PA.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apheresis
Description: Once subjects achieved a high antibody titer (\>1:160), they could begin apheresis to collect plasma.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apheresis
Description: Once subjects achieved a high antibody titer (\>1:160), they could begin apheresis to collect plasma.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apheresis
Description: Once subjects achieved a high antibody titer (\>1:160), they could begin apheresis to collect plasma.
Study: NCT01707329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Docetaxel 60-75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib+chemotherapy
Description: Icotinib: 125 mg is administered orally three times per day. Chemotherapy: docetaxel 75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
Study: NCT00383071

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apheresis
Description: Once subjects achieved a high antibody titer (\>1:160), they could begin apheresis to collect plasma.
Study: NCT02983240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Uterine Pacemaker
Description: The catheter is placed under ultrasound guidance into the posterior vaginal fornix next to the external cervical os. The electrode connectors are attached to the EI device. Activating the EI device involves: 1) turning the current pulse duration rotary dial clockwise to the desired setting; this is an important setting and should be set at 20ms; 2) turning the current frequency rotary dial clockwise to the desired setting; 3) turn on the EI device on with the on/off toggle switch; 4) SLOWLY turning the current strength rotary dial clockwise to the desired setting, at this time the red light should be flashing. Usually 5-10mA of current is sufficient, but 20 mA is a maximum. Based on the tocometer recordings the least amount of EI current is given to inhibit the uterine contractions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Uterine Pacemaker
Description: The catheter is placed under ultrasound guidance into the posterior vaginal fornix next to the external cervical os. The electrode connectors are attached to the EI device. Activating the EI device involves: 1) turning the current pulse duration rotary dial clockwise to the desired setting; this is an important setting and should be set at 20ms; 2) turning the current frequency rotary dial clockwise to the desired setting; 3) turn on the EI device on with the on/off toggle switch; 4) SLOWLY turning the current strength rotary dial clockwise to the desired setting, at this time the red light should be flashing. Usually 5-10mA of current is sufficient, but 20 mA is a maximum. Based on the tocometer recordings the least amount of EI current is given to inhibit the uterine contractions.